Where does BOLD stock trade?

Boundless Bio Inc. (BOLD) is listed on NASDAQ.

What sector and industry is BOLD in?

Boundless Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did Boundless Bio Inc. go public?

Boundless Bio Inc. (BOLD) completed its IPO in 2024.

What are analysts saying about BOLD?

Boundless Bio Inc. has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $500.00 price target on 2025-06-02. Recent price targets range from $300.00 to $500.00.

What companies are similar to BOLD?

Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BOLD side-by-side with any of them on Quantisnow.

How can I track BOLD on Quantisnow?

Quantisnow aggregates Boundless Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BOLD to receive live email and push alerts on every new disclosure.

BOLD

NASDAQ

Boundless Bio Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2024

$1.43-0.05 (-3.39%)

News25/Ratings3

News · 26 weeks21-100%

2025-12-142026-06-07

Mix890d

SEC Filings5(63%)
Other3(38%)

Latest news

25 items

31dSEC
SEC Form 10-Q filed by Boundless Bio Inc.
10-Q - Boundless Bio, Inc. (0001782303) (Filer)
31dSEC
Boundless Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Boundless Bio, Inc. (0001782303) (Filer)
31dPR
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026. "We are encouraged by the progress of the KOMODO-1 trial," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. "We continue to exp
40dSEC
SEC Form DEFA14A filed by Boundless Bio Inc.
DEFA14A - Boundless Bio, Inc. (0001782303) (Filer)
40dSEC
SEC Form DEF 14A filed by Boundless Bio Inc.
DEF 14A - Boundless Bio, Inc. (0001782303) (Filer)
51dPR
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical data supporting its lead ecDNA-directed therapy (ecDTx), BBI-940, at the American Association for Cancer Research (AACR) Annual Meeting 2026. Boundless has identified a novel kinesin target ("Kinesin") essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. BBI-940, a potentially first-in-class, oral, and selective Kinesin degrader, is currently being evaluated in th
55dSEC
Boundless Bio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation
8-K - Boundless Bio, Inc. (0001782303) (Filer)
82dPR
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation on their oral Kinesin degrader program at the American Association for Cancer Research (AACR) Annual Meeting 2026, which is being held April 17 – 22, in San Diego, CA. Boundless has identified a novel kinesin target ("Kinesin") essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. Boundless is developing BBI-940, a potentially first-in-c
91dSEC
SEC Form 10-K filed by Boundless Bio Inc.
10-K - Boundless Bio, Inc. (0001782303) (Filer)
91dSEC
Boundless Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
8-K - Boundless Bio, Inc. (0001782303) (Filer)
91dPR
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter and full year ended December 31, 2025. "With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited to evaluate this potentially first-in-c
96dPR
Boundless Bio to Participate in the Leerink Global Healthcare Conference
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Leerink Global Healthcare Conference. The fireside chat session is scheduled for Wednesday, March 11, in Miami, Florida at 11:20 a.m. ET. A live and archived webcast of the session will be accessible under "Events & Presentations" in the Investors section of Boundless Bio's website. About Boundless BioBoundless
97dPR
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth. Recently published Biliary Tract Cancer Market Insights report includes a comprehensive understanding of current
122dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Boundless Bio Inc.
SCHEDULE 13G/A - Boundless Bio, Inc. (0001782303) (Subject)
123dPR
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. The fireside chat session is scheduled for Thursday, February 12, in New York, NY, at 3:00 p.m. ET. A live and archived webcast of the session will be accessible under "Events & Presentations" in the Investors section of Boundless Bio's website. About Boundless Bi
133dINSIDER
SEC Form 4 filed by Officer Oien Jessica
4 - Boundless Bio, Inc. (0001782303) (Issuer)
133dINSIDER
SEC Form 4 filed by Chief Scientific Officer Hassig Christian
4 - Boundless Bio, Inc. (0001782303) (Issuer)
133dINSIDER
SEC Form 4 filed by Officer Hinkle David A
4 - Boundless Bio, Inc. (0001782303) (Issuer)
133dINSIDER
SEC Form 4 filed by President & CEO Hornby Zachary
4 - Boundless Bio, Inc. (0001782303) (Issuer)
133dINSIDER
SEC Form 4 filed by Chief Medical Officer Doebele Robert
4 - Boundless Bio, Inc. (0001782303) (Issuer)
139dPR
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second half of 2028 SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its novel Kinesin oral degrader program, BBI-940. The Company also provided
185dSEC
SEC Form SCHEDULE 13G filed by Boundless Bio Inc.
SCHEDULE 13G - Boundless Bio, Inc. (0001782303) (Subject)
196dPR
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (NASDAQ:BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. The fireside chat session is scheduled for Wednesday, December 3, in New York, NY, at 9:30 a.m. ET. A live and archived webcast of the session will be accessible under "Events & Presentations" in the Investors section of Boundless Bio's website. About Boundless Bio
215dSEC
SEC Form 10-Q filed by Boundless Bio Inc.
10-Q - Boundless Bio, Inc. (0001782303) (Filer)
215dSEC
Boundless Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Boundless Bio, Inc. (0001782303) (Filer)

BOLD FAQ

6 questions

Where does BOLD stock trade?
Boundless Bio Inc. (BOLD) is listed on NASDAQ.
What sector and industry is BOLD in?
Boundless Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did Boundless Bio Inc. go public?
Boundless Bio Inc. (BOLD) completed its IPO in 2024.
What are analysts saying about BOLD?
Boundless Bio Inc. has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $500.00 price target on 2025-06-02. Recent price targets range from $300.00 to $500.00.
What companies are similar to BOLD?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BOLD side-by-side with any of them on Quantisnow.
How can I track BOLD on Quantisnow?
Quantisnow aggregates Boundless Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BOLD to receive live email and push alerts on every new disclosure.